### Warfarin

**Indication**
Cerebral ischaemic stroke due to embolic occlusion  
**ICD11 code:** 8B11.2

**INN**
Warfarin

**Medicine type**
Chemical agent

**List type**
Core (EML)  
Complementary (EMLc)

**Formulations**
Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)  
(EMLc)

**EML status history**
- First added in 1977 (TRS 615)  
- Changed in 1979 (TRS 641)  
- Changed in 1982 (TRS 685)  
- Changed in 1987 (TRS 770)  
- Changed in 2007 (TRS 950)  
- Changed in 2021 (TRS 1035)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
Therapeutic alternatives to be reviewed (2023)

**Therapeutic alternatives limitations for EMLc**
Therapeutic alternatives to be reviewed (2023)

**Patent information**
Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**
[Warfarin](https://en.wikipedia.org/wiki/Warfarin)

**DrugBank**
[Warfarin](https://www.drugbank.ca/drugs/DB00001)